Last10K.com

Incyte Corp (INCY) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

Incyte Corp

CIK: 879169 Ticker: INCY

Exhibit 99.1

Graphic

FOR IMMEDIATE RELEASE

Incyte Reports 2021 Fourth Quarter and Year-end Financial Results, and

Provides 2022 Financial Guidance and Updates on Key Clinical Programs

-Total product and royalty revenues of $813 million (+20%) in Q4’21 and $2.891 billion (+17%) in FY’21
-Jakafi® (ruxolitinib) net product revenues of $592 million (+15%) in Q4’21 and $2.135 billion (+10%) in FY’21; Jakafi guidance range of $2.3 to $2.4 billion for 2022
-Successful U.S. launch of OpzeluraTM (ruxolitinib) cream in atopic dermatitis with nearly 19,000 patients treated from launch (October 11th) through the end of the year
-Vitiligo is the next substantial growth opportunity for ruxolitinib cream – under Priority Review in the U.S. and under review in Europe

Conference Call and Webcast Scheduled Today at 8:00 a.m. EDT

WILMINGTON, Del. – February 8, 2022

 – Incyte (Nasdaq:INCY) today reports 2021 fourth quarter financial results, provides 2022 financial guidance and a status update on the Company’s clinical development portfolio.

“2021 was a year of important accomplishments for Incyte. Growth of product and royalty revenues was strong, led by robust demand for Jakafi® (ruxolitinib), continued uptake of Pemazyre® (pemigatinib) in the U.S., and a rapidly growing royalty revenue stream. Throughout the year, we significantly expanded our commercial portfolio with several new approvals, including Pemazyre® (pemigatinib) in cholangiocarcinoma (CCA) in Europe and Japan; Minjuvi® (tafasitamab) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in Europe; and, in the U.S., both Jakafi in steroid-refractory chronic graft-versus-host disease (GVHD) and OpzeluraTM (ruxolitinib) cream in atopic dermatitis,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “Our launch of Opzelura has been very successful thus far. Nearly 19,000 patients were treated in the fourth quarter and feedback from both dermatologists and patients has been very positive. Importantly, we have also made significant progress towards ensuring optimal patient access to Opzelura.”

Portfolio Updates

MPNs and GVHD – key highlights

Axatilimab (anti-CSF-1R monoclonal antibody) in chronic GVHD: In December, updated positive data from the Phase 1/2 trial evaluating axatilimab as a monotherapy in patients with recurrent or refractory chronic GVHD despite two or more prior lines of therapy were presented at ASH. A 68% overall response rate

1


The following information was filed by Incyte Corp (INCY) on Tuesday, February 8, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Incyte Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Incyte Corp.

Continue

Assess how Incyte Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Incyte Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Revenue
Financial
Other
Filter by Subcategory:
All
Product
Expense
Income
Earnings
Debt
Other
Inside Incyte Corp's 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Cash Flows (Parenthetical)
Consolidated Statements Of Comprehensive Income
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders' Equity
Consolidated Statements Of Stockholders' Equity (Parenthetical)
Accrued And Other Current Liabilities
Accrued And Other Current Liabilities (Details)
Accrued And Other Current Liabilities (Tables)
Commitments And Contingencies
Commitments And Contingencies - Commitments (Details)
Commitments And Contingencies - Contingencies (Details)
Concentrations Of Credit Risk And Current Expected Credit Losses
Concentrations Of Credit Risk And Current Expected Credit Losses (Details)
Concentrations Of Credit Risk And Current Expected Credit Losses (Tables)
Employee Benefit Plans
Employee Benefit Plans (Tables)
Employee Benefit Plans - Defined Benefit Pension Plan (Details)
Employee Benefit Plans - Defined Contribution Plan (Details)
Employee Benefit Plans - Expected Benefit Payments (Details)
Employee Benefit Plans - Net Periodic Benefit Cost (Details)
Employee Benefit Plans - Other Changes In The Plan Assets And Benefit Obligation (Details)
Fair Value Of Financial Instruments
Fair Value Of Financial Instruments (Tables)
Fair Value Of Financial Instruments - Fair Value On A Recurring Basis (Details)
Fair Value Of Financial Instruments - Marketable Securities Portfolio (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Income Before Provision (Details)
Income Taxes - Narrative And Unrecognised Tax Benefits (Details)
Income Taxes - Nol (Details)
Income Taxes - Provision For Income Taxes (Details)
Income Taxes - Reconciliation Of Income Taxes (Details)
Income Taxes - Tax Credit Carryforwards (Details)
Intangible Assets And Goodwill
Intangible Assets And Goodwill (Details)
Intangible Assets And Goodwill (Tables)
Inventory
Inventory (Details)
Inventory (Tables)
License Agreements
License Agreements - Agenus (Details)
License Agreements - Calithera (Details)
License Agreements - Innocare (Details)
License Agreements - Innovent (Details)
License Agreements - Lilly (Details)
License Agreements - Macrogenics (Details)
License Agreements - Merus (Details)
License Agreements - Morphosys (Details)
License Agreements - Nimble (Details)
License Agreements - Novartis (Details)
License Agreements - Syndax (Details)
License Agreements - Syros (Details)
License Agreements - Zai Lab (Details)
Net Income (Loss) Per Share
Net Income (Loss) Per Share (Details)
Net Income (Loss) Per Share (Tables)
Organization And Summary Of Significant Accounting Policies
Organization And Summary Of Significant Accounting Policies (Details)
Property And Equipment, Net
Property And Equipment, Net (Tables)
Property And Equipment, Net - Buildings And Construction (Details)
Property And Equipment, Net - Lease And Maturity Of Lease Liabilities (Details)
Property And Equipment, Net - Property And Equipment, Net (Details)
Revenues
Revenues (Details)
Revenues (Tables)
Segment Information
Segment Information (Details)
Stock Compensation
Stock Compensation (Details)
Stock Compensation (Tables)
Stock Compensation - Rsu And Psu Award Activity (Details)
Stockholders' Equity
Stockholders' Equity (Tables)
Stockholders' Equity - Employee Stock Purchase Plan (Details)
Stockholders' Equity - Option Activity (Details)
Stockholders' Equity - Preferred Stock And Common Stock (Details)
Stockholders' Equity - Rsu And Psu Narrative (Details)
Stockholders' Equity - Shares Available For Grant (Details)
Stockholders' Equity - Stock Compensation Plans (Details)
Stockholders' Equity - Stock Options Outstanding (Details)
Summary Of Significant Accounting Policies (Policies)
Ticker: INCY
CIK: 879169
Form Type: 10-K Annual Report
Accession Number: 0001558370-22-000902
Submitted to the SEC: Tue Feb 08 2022 4:05:11 PM EST
Accepted by the SEC: Tue Feb 08 2022
Period: Friday, December 31, 2021
Industry: Commercial Physical And Biological Research

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/incy/0001558370-22-000902.htm